Small Molecules

29 Jun 2018 Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
29 Jun 2018 FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
29 Jun 2018 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis
29 Jun 2018 Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
29 Jun 2018 Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine
29 Jun 2018 Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
29 Jun 2018 Topline results of PELICAN trial and update on triple combo development plans
28 Jun 2018 Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28 Jun 2018 Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
28 Jun 2018 Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy
28 Jun 2018 Kangpu Biopharmaceuticals Launched Phase I Study of Novel Cancer Therapy Candidate KPG-121 in Patients with Metastatic Castration-Resistant Prostate Cancer in Collaboration with Accelovance, Inc.
28 Jun 2018 Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome
28 Jun 2018 Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)
27 Jun 2018 U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
27 Jun 2018 Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
27 Jun 2018 AcelRx receives European Commission approval for DZUVEO™
27 Jun 2018 Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
27 Jun 2018 GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
27 Jun 2018 Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
27 Jun 2018 Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression
27 Jun 2018 LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
27 Jun 2018 Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies
27 Jun 2018 Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
27 Jun 2018 MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
27 Jun 2018 ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up